Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference

Rhea-AI Summary

Cybin, a biopharmaceutical company focused on developing therapeutics from psychedelics, announces CEO Doug Drysdale's participation in two virtual investor conferences. The first is the 11th Annual LifeSci Partners Annual Corporate Access Event from January 5-7, 2022, where he will discuss psychedelics on January 5 at 10:00 a.m. ET. The second is the H.C. Wainwright Bioconnect Conference from January 10-13, 2022, featuring a fireside chat available on-demand starting January 10 at 7:00 a.m. ET. More details can be accessed through the company's investor relations website.

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in two upcoming virtual investor conferences as follows:

11^th Annual LifeSci Partners Annual Corporate Access Event, January 5-7, 2022

Mr. Drysdale will participate in a panel discussion titled “Psychedelics: More Than Just a Trip” on Wednesday, January 5, 2022 at 10:00 a.m. ET. Please click here to register and access the webcast.

H.C. Wainwright Bioconnect Conference, January 10-13, 2022

Mr. Drysdale will participate in a fireside chat at the H.C. Wainwright Bioconnect Conference being held virtually on Monday, January 10, 2022.

The fireside chat will be available on-demand beginning on January 10, 2022 at 7:00 a.m. ET. To listen to the event, please click here to register and access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics™ by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005177/en/

Investors & Media:

Leah Gibson

Vice President, Investor Relations

Cybin Inc.

leah@cybin.com

Source: Cybin Inc.

FAQ

What is Cybin's focus in the biopharmaceutical industry?

Cybin is focused on developing therapeutics from psychedelics to address mental health issues.

When will Cybin's CEO Doug Drysdale participate in the LifeSci Partners event?

Doug Drysdale will participate in the LifeSci Partners event on January 5, 2022, at 10:00 a.m. ET.

What is the date for the H.C. Wainwright Bioconnect Conference?

The H.C. Wainwright Bioconnect Conference will take place from January 10-13, 2022.

When will the fireside chat at the H.C. Wainwright Conference be available?

The fireside chat will be available on-demand starting January 10, 2022, at 7:00 a.m. ET.

How can I access the webcasts for Cybin's investor conferences?

Webcasts can be accessed through Cybin's investor relations website and by registering for the events.